1. Home
  2. STLA vs UTHR Comparison

STLA vs UTHR Comparison

Compare STLA & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stellantis N.V.

STLA

Stellantis N.V.

HOLD

Current Price

$7.73

Market Cap

19.4B

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$572.28

Market Cap

25.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STLA
UTHR
Founded
2021
1996
Country
Netherlands
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.4B
25.1B
IPO Year
2014
1999

Fundamental Metrics

Financial Performance
Metric
STLA
UTHR
Price
$7.73
$572.28
Analyst Decision
Buy
Buy
Analyst Count
5
14
Target Price
$11.59
$567.57
AVG Volume (30 Days)
18.6M
441.7K
Earning Date
02-26-2026
05-06-2026
Dividend Yield
7.35%
N/A
EPS Growth
N/A
13.07
EPS
N/A
27.86
Revenue
N/A
$1,483,300,000.00
Revenue This Year
$7.18
$6.39
Revenue Next Year
$3.50
$14.18
P/E Ratio
N/A
$20.44
Revenue Growth
N/A
2.38
52 Week Low
$6.28
$272.18
52 Week High
$12.22
$607.89

Technical Indicators

Market Signals
Indicator
STLA
UTHR
Relative Strength Index (RSI) 46.00 54.29
Support Level $7.07 $464.92
Resistance Level $8.27 $593.65
Average True Range (ATR) 0.21 12.32
MACD -0.06 -3.50
Stochastic Oscillator 2.61 27.04

Price Performance

Historical Comparison
STLA
UTHR

About STLA Stellantis N.V.

Stellantis was created out of the merger of US-based Fiat Chrysler Automobiles and French-based Peugeot in January 2021, resulting in the fourth-largest automotive original equipment manufacturer by vehicle sales. In 2024 it sold 5.5 million vehicles, 47%, 26% and 17% in Europe, North America, and South America, respectively. Its brands include Fiat, Jeep, Chrysler, Ram, Peugeot, Citroën, Opel, Alfa Romeo, and Maserati.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: